Danyelza (Naxitamab-Gqgk) Patent Expiration, LOE Window & CMS Spending
Danyelza (Naxitamab-Gqgk) by Y-Mabs Therapeutics: Biologic BLA (Purple Book Regime), 0 AB generics, $13.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Y-Mabs Therapeutics |
| FDA Application & Pathway | B761171 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $13.1M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $13.1M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.8% 2-yr change) |